Skip to main content
Fig. 6 | Diabetology & Metabolic Syndrome

Fig. 6

From: Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathway

Fig. 6

Dapagliflozin upregulated the expression of ABCA1 and KLF-5 in DN. (A) WB revealed that dapagliflozin could upregulate the expression of ABCA1 and KLF-5, which were downregulated in the DN group, significantly during in vivo experiments. (B) IHC showed that the expression of ABCA1 and KLF-5 were significantly downregulated in the DN group, while dapagliflozin treatment could upregulate it. (Data presented are the mean ± S.D.; *P < 0.05 vs. CTR, # P < 0.05 vs. DN, n = 3)

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us